BA
NBIX icon

Boston Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Boston Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-30,608
Closed -$3.76M – 652
2018
Q3 		$3.76M Sell
30,608
-100,873
-77% -$11.4M 0.16% 207
2018
Q2 		$12.9M Buy
131,481
+111,896
+571% +$10M 0.32% 76
2018
Q1 		$1.62M Buy
19,585
+7,100
+57% +$600K 0.04% 295
2017
Q4 		$969K Buy
+12,485
New +$852K 0.02% 372

Other funds holding NBIX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Boston Advisors's NBIX Position: Q4 2018 in Review

Boston Advisors sold out of Neurocrine Biosciences (NBIX) in Q4 2018, closing a stake of 30,608 shares — an estimated $3.76M sold.

Boston Advisors first reported a position in NBIX in Q4 2017 and held it in 4 quarters. The position peaked at $12.9M in Q2 2018. 330 funds tracked by Wall St. Rank hold NBIX as of Q4 2018.

  • Boston Advisors reported no remaining Neurocrine Biosciences position as of Q4 2018 after selling out during the quarter.
  • Boston Advisors sold 30,608 Neurocrine Biosciences shares in Q4 2018, an estimated $3.76M.
  • Boston Advisors first reported a position in Neurocrine Biosciences in Q4 2017 and held it in 4 quarters.
  • Boston Advisors's Neurocrine Biosciences position peaked at $12.9M in Q2 2018.
  • 330 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2018.

Based on Boston Advisors's 13F filing for Q4 2018, filed 16 Jan 2019.